Not saying this is a result that should be taken as definite, but it's strong enough to warrant further looking into this (which was never really true for hydroxychloroquine).
https://www.connexionfrance.com/French-news/French-researche...
Don't get me wrong, this whole thing is a fucking mess.
I haven't seen a reliable study that shows HCQ is effective. I'd be happy to see one of you have one? Given the attention paid to this molecule, there should be some nice, randomised control trials with large n numbers.
It would be more interesting to look at (say) NHS data. That's the quick way to avoid this sort of guessing...
https://www.pfizer.com/news/press-release/press-release-deta....
Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol, of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group. Efficacy was consistent across age, gender, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%.
[1] https://www.cdc.gov/chickenpox/outbreaks/downloads/appx-f-in...
>Findings In this randomized trial that included 152 adult outpatients with confirmed COVID-19 and symptom onset within 7 days, clinical deterioration occurred in 0 patients treated with fluvoxamine vs 6 (8.3%) patients treated with placebo over 15 days, a difference that was statistically significant.
It honestly worries me how quick people are to jump on these band wagons. Call me when you've at least got 100 cases to review.